Sempatomimetik İlaç Zehirlenmeleri

Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;32: 639-677.

Hoffman BB, Lefkowitz RJ. (1996).Catecholamines, sympath- omimetic drugs, and adrenergic receptor antagonists. In J.G. Hardman, L.Ê. Limbird, & P.B. Molinoff et al (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics (9th ed., pp. 199-227). New York, NY: McGraw-Hill.

Williams RH, Erickson T, Broussard LA. Evaluating sympathomimetic intoxication in an emergency setting. Laboratory Medicine. 2000: 31(9):497-508.

Shannon M. Clinical toxicity of cocaine adulterants. Ann Emerg Med. 1988;17:1243-1247.

Stewart DJ, Inaba T, Lucassen M, et al. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther. 1979;25:464-468.

Isenschmid DS. (1999).Cocaine. In B. Levine (Ed.), Principles of Forensic Toxicology (pp. 221-245).Washington, DC: AACC Press.

Brookoff D, Rotondo MF, Shaw LM, et al. Cocaethylene levels in patients who test positive for cocaine. Ann Emerg Med. 1996;27:316-320.

Henning RJ, Wilson LD, Glauser JM. Cocaine plus ethanol is more car- diotoxic than cocaine or ethanol alone. Crit Care Med. 1994;22:1896-1906.

Weis RD, Gawin FH. Protracted elimination of cocaine metabolites in long-term high dose cocaine abuse. Am J Med. 1988;85:879-880.

Hollander JE. Management of cocaine-associated myocardial ischemia.N Engl J Med. 1995;333:1267-1272.

Hollander JE, Hoffman RS. (1998). Cocaine. In L.R. Goldfrank, N.E. Flomenbaum, N.A. Lewin (Eds), Goldfrank’s Toxicologic Emergencies (6th Ed., pp.1071-1089) Stamford, CT: Appleton & Lange.

Gitter MJ, Goldsmith ER, Dunbar DN, et al. Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med. 1991;115:277-282.

Glennon RA. Stimulation properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationship. NIDA Res Monogr. 1989;94:43-67.

Battaglia G, DeSouza EB. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr. 1989;94:240-248.

Moore K. (1999). Amphetamines/sympathomimetic amines. In B. Levine (Ed.), Principles of Forensic Toxicology (pp. 265-284). Washington, DC: AACC Press.

Blum K. (1984). Central nervous system stimulants. In K. Blum (Ed.), Handbook of Arousable Drugs (pp. 305-347). New York, NY: Gardner.

Greenblatt JC, Gfroerer JC, Melnick D. Increasing morbid- ity and mortality associated with abuse of methamphetamine United States, 1991-1994. MMWR Morb Mortal Wkly Rep. 1995;44:882-886.

Chiang WK, Goldfrank LR: Substance withdrawal. Emerg Med Clin North Am. 1990;8:613-631.

Nichols DE, Oberlender R. Structure-activity relationships of MDMA-like substances. NIDA Res Monogr. 1989;94:1-29.

Randall T. Ecstasy-fueled “rave” parties become dances of death for English youths. JAMA. 1992;268:1505-1506.

Randall T. “Rave” scene, ecstasy use, leap Atlantic.JAMA. 1992;268:1506.

De Souza EB, Battaglia G. Effects of MDMA and DA on brain serotonin neurons: evidence from neurochemical and autoradiographic studies. NIDA Res Monogr. 1989;94:196-222.

Simpson DL, Rumack BH. Methylenedioxymethamphetamine: clinical description of overdose, death, and review of pharmacology. Arch Intern Med. 1981;141:1507-1509.

Kalix P. Pharmacological properties of the stimulant khat. Pharmacol Ther. 1990;48:397-416.

Chiang WK. Amphetamines. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank’s Toxicologic Emergencie.s 6th ed. Stamford, CT: Appleton & Lange; 1998:1091-1103.

Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med. 1977;86:381-387.

Hoffman RS, Hollander JE. Thrombolytic therapy in cocaine-induced myocardial infarction. Am J Emerg Med. 1996;14:693-695.